Compositions and methods for treatment of eye disorders

Details Compositions and methods for treatment of eye disorders Compositions and methods for treatment of eye disorders

2009-07-23

2011-12-27

Padmanabhan, Sreeni (Department: 1627)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

C514S309000

Reexamination Certificate

active

08084047

ABSTRACT:
The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

REFERENCES:
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5149780 (1992-09-01), Plow et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5298492 (1994-03-01), Neustadt et al.
patent: 5340800 (1994-08-01), Liu et al.
patent: 5397791 (1995-03-01), Hartman et al.
patent: 5424399 (1995-06-01), Arnaout
patent: 5470953 (1995-11-01), Gallatin et al.
patent: 5585359 (1996-12-01), Breslin et al.
patent: 5597567 (1997-01-01), Whitcup et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5747035 (1998-05-01), Presta et al.
patent: 5973188 (1999-10-01), Alig et al.
patent: 6204280 (2001-03-01), Gante et al.
patent: 6294522 (2001-09-01), Zablocki et al.
patent: 6331640 (2001-12-01), Fotouhi et al.
patent: 6340679 (2002-01-01), Peyman et al.
patent: 6358976 (2002-03-01), Wityak et al.
patent: 6515124 (2003-02-01), Fotouhi et al.
patent: 6524581 (2003-02-01), Adamis
patent: 6605597 (2003-08-01), Zablocki et al.
patent: 6653478 (2003-11-01), Urbanski et al.
patent: 6667318 (2003-12-01), Burdick et al.
patent: 6670321 (2003-12-01), Adamis
patent: 6803384 (2004-10-01), Fotouhi et al.
patent: 6872382 (2005-03-01), Gamache et al.
patent: 6872735 (2005-03-01), Burdick et al.
patent: 7211586 (2007-05-01), Fenton et
patent: 7217728 (2007-05-01), Fotouhi et al.
patent: 7314938 (2008-01-01), Shen et al.
patent: 2001/0031260 (2001-10-01), Lee et al.
patent: 2002/0115692 (2002-08-01), Archibald et al.
patent: 2002/0119994 (2002-08-01), Burdick et al.
patent: 2002/0132807 (2002-09-01), Wang et al.
patent: 2002/0177591 (2002-11-01), O'Donnell et al.
patent: 2003/0044406 (2003-03-01), Dingivan
patent: 2003/0068320 (2003-04-01), Dingivan
patent: 2003/0166630 (2003-09-01), Auvin et al.
patent: 2004/0006236 (2004-01-01), Fotouhi et al.
patent: 2004/0028648 (2004-02-01), Adamis
patent: 2004/0058968 (2004-03-01), Burdick et al.
patent: 2004/0120960 (2004-06-01), Jardieu et al.
patent: 2005/0080119 (2005-04-01), Fotouhi et al.
patent: 2005/0148588 (2005-07-01), Burdick et al.
patent: 2005/0267098 (2005-12-01), Shen et al.
patent: 2006/0281739 (2006-12-01), Gadek et al.
patent: 2007/0025990 (2007-02-01), Dingivan
patent: 2007/0155671 (2007-07-01), Fotouhi et al.
patent: 2008/0176896 (2008-07-01), Shen et al.
patent: 2008/0182839 (2008-07-01), Shen et al.
patent: 2009/0155176 (2009-06-01), Burnier et al.
patent: 2010/0092541 (2010-04-01), Burnier et al.
patent: 0314863 (1989-05-01), None
patent: 0314863 (1990-04-01), None
patent: 0362526 (1990-04-01), None
patent: 0362531 (1990-04-01), None
patent: 0362526 (1990-07-01), None
patent: 0656789 (1997-12-01), None
patent: 1392306 (2008-01-01), None
patent: 4193895 (1992-07-01), None
patent: WO 90/03400 (1990-04-01), None
patent: WO 90/10652 (1990-09-01), None
patent: WO 90/13316 (1990-11-01), None
patent: WO 91/19511 (1991-12-01), None
patent: WO 92/03473 (1992-03-01), None
patent: WO 94/03481 (1994-02-01), None
patent: WO 94/11400 (1994-05-01), None
patent: WO 95/04531 (1995-02-01), None
patent: WO 95/28170 (1995-10-01), None
patent: WO 96/09836 (1996-04-01), None
patent: WO 98/46599 (1998-10-01), None
patent: WO 99/49856 (1999-10-01), None
patent: WO 99/49856 (1999-11-01), None
patent: WO 00/21920 (2000-04-01), None
patent: WO 00/38714 (2000-07-01), None
patent: WO 00/44731 (2000-08-01), None
patent: WO 01/27102 (2001-04-01), None
patent: WO 01/58853 (2001-08-01), None
patent: WO 01/87840 (2001-11-01), None
patent: WO 02/50080 (2002-06-01), None
patent: WO 02/059114 (2002-08-01), None
patent: WO 02/098426 (2002-12-01), None
patent: WO 2004/026406 (2004-04-01), None
patent: WO 2005/014532 (2005-02-01), None
patent: WO 2005/014533 (2005-02-01), None
patent: WO 2005/014533 (2005-04-01), None
patent: WO 2005/044817 (2005-05-01), None
patent: WO 2005/123706 (2005-12-01), None
Wermuth, The Practice of Medicinal Chemistry—Molecular Variations Based on Isosteric Replacements, 1996, Academic Press Limited, pp. 203 and 226-228.
Hecht et al., Effects of Methyl and Fluorine Substitution on the Metabolic Activation and Tumorigenitity of Polycyclin Aromatic Hydrocarbons, Polycyclic Hydrocarbons and Carcinogenesis, 1985 ACS Symposium Series, vol. 283, Chapter 5, printed from http://pubs.acs.org/doi/abs/10.1021/bk-1985-0283.ch005, Abstract only, 1 page.
Crocker et al.,The Role of the Role of Fluorine Substitution in the Structure-Activity Relationships (SAR) of Classical Cannabinoids, Bioorg Med Chem Lett. Mar. 15, 2007; 17(6), printed from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855243/?report=abstract, Abstract only, 1 page.
Boschelli, et al. 3-Alkoxybenzo[b]thiophene-2-carboxamides as inhibitors of neutrophil-endothelial cell adhesion. J Med Chem. 1994; 37(6): 717-8.
Boschelli, et al. Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-mediated cell adhesion by benzo[b]thiophene-, benzufuran-, indole-, and naphthalene-2-carboxamides: Identification of PD 144795 as an antiinflammatory agent. J Med Chem. 1995; 38: 4597-614.
Burdick, et al. N-Benzoyl amino acids as ICAM/LFA-1 inhibitors. Part 2: Structure-activity relationship of the benzoyl moiety. Bioorganic & Medicinal Chemistry Letters. 2004; 14(9): 2055-9.
Burdick, et al. N-Benzoyl amino acids as LFA-1/ICAM inhibitors 1: amino acid structure-activity relationship. Bioorganic & Medicinal Chemistry Letters. 2004; 13(6): 1015-8.
Chang, et al. Effects of pharmacologic agents on the reversed passive Arthus reaction in the rat. Eur J Pharmacol. 1981; 69(2): 155-64.
Chavanpatil, et al. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm. 2006; 316(1-2): 86-92.
Coleman, et al. Chemoselective Cleavage of Benzyl Ethers, Esters, and Carbamates in the Presence of Other Easily Reducible Groups. Synthesis. 1999;1399-1400.
Cosimi, et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol. 1990; 144(12): 4604-12.
Diamond, et al. The dynamic regulation of integrin adhesiveness. Current Biology. 1994; 4(6): 506-32.
European search report dated May 20, 2009 for Application No. 06770607.7.
Fischer, et al. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation. The Lancet. 1986; 2: 1058-60.
Fox. Systemic diseases associated with dry eye. Int Ophthalmol Clin, 1994; 34(1):71-87.
Gadek, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science. 2002; 295: 1086-9.
Gao, et al. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Exp Eye Res. Apr. 2004;78(4):823-35.
Gorski, A. The role of cell adhesion molecules in immunopathology. Immunology Today. 1994; 15: 251-5.
Hildreth, et al. Monoclonal antibodies against porcine LFA-1: Species cross-reactivity and functional effects of β-subunit-specific antibodies. Molecular Immunology. 1989; 26(9): 883-95.
Hoffman, et al. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm. 2004; 277(1-2): 141-53.
Huang, et al. A binding interface of the I domain of lymphocyte function-associated antigen-1 (LFA-1) required for specific interaction with intercellular adhesion molecule 1 (ICAM-1). J Biological Chemistry. 1995; 270(32): 19008-16.
International search report dated Sep. 19, 2006 for PCT Application No. PCT/US2006/19327.
Kavanaugh, et al. Treatment of refractory

Affiliated with

Also associated with

Rating

Compositions and methods for treatment of eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treatment of eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of eye disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4298248